Neurosterix (Group)

https://www.neurosterix.com

Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company pioneering allosteric modulation-based drug development, and funds affiliated with Perceptive Advisors, an investment management firm focused on the life sciences sector, in early April 2024 announced the launch of Neurosterix, a company focused on developing allosteric modulators for the treatment of underserved neurological disorders. With initial funding of $63 million from Perceptive Xontogeny Venture Fund II, with participation from Perceptive Life Sciences Fund and Acorn Bioventures, Neurosterix will acquire a portfolio of preclinical assets and the allosteric modulator drug discovery technology platform from Addex and accelerate their development. In return, Addex will receive CHF5 million and a 20% equity interest in Neurosterix. Addex will retain its partnerships with Janssen Pharmaceuticals, Inc. and Indivior PLC, as well as unpartnered clinical stage assets including dipraglurant for Parkinson’s disease and post-stroke/TBI recovery as well as its preclinical GABAB positive allosteric modulator (PAM) program for chronic cough. *

	Start	2024-03-13 established
	Predecessor	Addex Therapeutics S.A. (SIX: ADXN)
	Industry	pharmaceutical
	Person	Dyer, Tim (Addex CEO 201802 formerly CFO + Co-Founder)

	Region	Genève (Geneva) GE
	Country	Switzerland
	Street	9 Chemin des Mines
	City	1202 Genève GE
		Address record changed: 2024-04-03

Basic data	Employees	n. a.

		* Document for »About Section«: Addex Therapeutics S.A.. (4/3/24). "Press Release: Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders". Geneva & New York, NY.

		Record changed: 2024-04-13

Picture Kenes Exhibitions Biomed Israel 2024 Tel Aviv 650x200px

More documents for Neurosterix (Group)

[1] Addex Therapeutics S.A.. (4/3/24). "Press Release: Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders". Geneva & New York, NY....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)